Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAPTIMMUNE THERAPEUTICS PLC

(ADAP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société ADAPTIMMUNE THERAPEUTICS PLC
09/16ADAPTIMMUNE THERAPEUTICS : SURPASS ESMO poster September 16th, 2021th
PU
09/13PRESENTATION DECK FOR BUILDING A CEL : SURPASS Phase 1 trial data at ESMO September 13, 20..
PU
09/13BUILDING A CELL THERAPY FRANCHISE : SURPASS Phase 1 trial data at ESMO September 13, 2021
PU
09/13ADAPTIMMUNE THERAPEUTICS : Announces Clinical Responses across Five Solid Tumor Indication..
PU
09/13ADAPTIMMUNE THERAPEUTICS PLC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/13ADAPTIMMUNE THERAPEUTICS : Announces Clinical Responses across Five Solid Tumor Indication..
AQ
09/09ADAPTIMMUNE THERAPEUTICS : First live virtual event – our allogeneic platform
PU
09/09ADAPTIMMUNE THERAPEUTICS : Presentation deck for First live virtual event – our allo..
PU
09/07ADAPTIMMUNE THERAPEUTICS : Enters into a Strategic Collaboration with Genentech to Researc..
PU
09/07ADAPTIMMUNE THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Regulation FD D..
AQ
09/07ROCHE : Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Deve..
AQ
09/05ADAPTIMMUNE THERAPEUTICS : Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Sh..
AQ
08/20ADAPTIMMUNE THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Financial State..
AQ
08/13ADAPTIMMUNE THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Financial State..
AQ
08/09ADAPTIMMUNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and..
AQ
08/09ADAPTIMMUNE THERAPEUTICS PLC : Results of Operations and Financial Condition, Financial St..
AQ
08/09Adaptimmune Reports Second Quarter Financial Results and Business Update
GL
07/28Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9..
GL
06/01ADAPTIMMUNE THERAPEUTICS : June 2021 Corporate Deck
PU
05/19ADAPTIMMUNE THERAPEUTICS : Company Presentation of Data at ASCO 2021 Annual Meeting- PDF
PU
05/19ADAPTIMMUNE THERAPEUTICS : Two Complete Responses and Response Rate of 41% for People with..
PU
05/19ADAPTIMMUNE THERAPEUTICS PLC : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
05/19Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Report..
GL
05/14ADAPTIMMUNE THERAPEUTICS PLC : Submission of Matters to a Vote of Security Holders (form 8..
AQ
05/11First Preclinical Data from Adaptimmune's Mesothelin HiT Program at ASGCT Demonstrate A..
GL
05/06ADAPTIMMUNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and..
AQ
05/06ADAPTIMMUNE THERAPEUTICS PLC : Results of Operations and Financial Condition, Financial St..
AQ
05/06Adaptimmune Reports First Quarter Financial Results and Business Update
GL
04/27Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platfo..
GL
04/27ADAPTIMMUNE THERAPEUTICS : to Present First Preclinical Data from its HLA-independent TCR ..
AQ
04/22Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6,..
GL
04/08ADAPTIMMUNE THERAPEUTICS : Picture_as_pdf Notice of 2021 Annual General Meeting
PU
04/08ADAPTIMMUNE THERAPEUTICS : April 2021 Corporate Deck
PU
02/26ADAPTIMMUNE THERAPEUTICS : Reports Fourth Quarter Full Year 2020 Financial Results and Bus..
AQ
02/25ADAPTIMMUNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and..
AQ
02/25ADAPTIMMUNE THERAPEUTICS PLC : Results of Operations and Financial Condition, Financial St..
AQ
02/25ADAPTIMMUNE THERAPEUTICS : Reports Fourth Quarter / Full Year 2020 Financial Results and B..
AQ
02/11Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Upd..
GL
02/08ADAPTIMMUNE THERAPEUTICS : February 2021 Corporate Deck
PU
01/07ADAPTIMMUNE THERAPEUTICS : January 2021 Corporate Deck
PU
2020ADAPTIMMUNE THERAPEUTICS PLC : Change in Directors or Principal Officers, Financial Statem..
AQ
2020ADAPTIMMUNE THERAPEUTICS : Investor Day November 2020 Replay
PU
2020ADAPTIMMUNE THERAPEUTICS : Investor Day November 20, 2020
PU
2020ADAPTIMMUNE THERAPEUTICS : December 2020 Corporate Deck
PU
2020ADAPTIMMUNE THERAPEUTICS : Elliot Norry, Chief Medical Officer – SITC 2020 SURPASS P..
PU
2020ADAPTIMMUNE THERAPEUTICS : to Showcase Market Potential for SPEAR T-cell Portfolio and Pip..
AQ
2020ADAPTIMMUNE THERAPEUTICS : Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confir..
AQ
2020ADAPTIMMUNE THERAPEUTICS PLC : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
2020ADAPTIMMUNE THERAPEUTICS : to Showcase Market Potential for SPEAR T-cell Portfolio and Pip..
AQ
2020Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with M..
GL
2020ADAPTIMMUNE THERAPEUTICS PLC : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
2020Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of ..
GL
2020ADAPTIMMUNE THERAPEUTICS : Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confir..
AQ
2020ADAPTIMMUNE THERAPEUTICS : to Host Virtual Investor Day on Friday, November 20th
AQ
2020ADAPTIMMUNE THERAPEUTICS : to Host Virtual Investor Day on Friday, November 20th
AQ
2020Adaptimmune to Host Virtual Investor Day on Friday, November 20th
GL
2020ADAPTIMMUNE THERAPEUTICS : Elliot Norry, Chief Medical Officer – SITC 2020 Surpass P..
PU
2020ADAPTIMMUNE THERAPEUTICS PLC : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
2020ADAPTIMMUNE THERAPEUTICS : Two Confirmed Responses and Five out of Six Patients with Initi..
AQ
2020Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from..
GL
2020ADAPTIMMUNE THERAPEUTICS : Xbrl q3 2020
PU
2020ADAPTIMMUNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and..
AQ
2020ADAPTIMMUNE THERAPEUTICS PLC : Results of Operations and Financial Condition, Financial St..
AQ
2020ADAPTIMMUNE THERAPEUTICS : Reports Q3 Financial Results and Business Update
AQ
2020Adaptimmune Reports Q3 Financial Results and Business Update
GL
2020ADAPTIMMUNE THERAPEUTICS : to Report Q3 Financial Results and Business Update on Thursday,..
AQ
2020ADAPTIMMUNE THERAPEUTICS : to Report Q3 Financial Results and Business Update on Thursday,..
AQ
2020Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5,..
GL
2020ADAPTIMMUNE THERAPEUTICS : Provides Full Contents of its SITC Abstract for the Phase 1 SUR..
AQ
2020ADAPTIMMUNE THERAPEUTICS PLC : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
2020ADAPTIMMUNE THERAPEUTICS : Provides Full Contents of its SITC Abstract for the Phase 1 SUR..
AQ
2020Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
GL
2020ADAPTIMMUNE THERAPEUTICS : Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cance..
AQ
2020ADAPTIMMUNE THERAPEUTICS PLC : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
2020ADAPTIMMUNE THERAPEUTICS : August 2020 Corporate Deck
PU
1  2  3  4  5Next
Upcoming event on ADAPTIMMUNE THERAPEUTICS PLC